Disease damage by system/ organ at last follow up | Frequency (%) |
---|---|
Ocular | 9 (15.3%) |
 Cataract | 7 (11.9%) |
 Retinal change or optic atrophy | 2 (3.4%) |
Neuropsychiatric | 7 (11.9%) |
 Cognitive impairment or major psychosis | 3 (5.1%) |
 Seizures requiring therapy for 6 months | 3 (5.1%) |
 Cerebrovascular accident ever | 0 |
 Cranial or peripheral neuropathy | 1 (1.7%) |
 Transverse myelitis | 0 |
Renal | 2 (3.4%) |
 Estimated or measured GFR < 50% | 0 |
 Proteinuria (nephrotic range proteinuria) | 0 |
 End-stage renal disease | 2 (3.4%) |
Pulmonary a | 0 |
Cardiovascular | 2 (3.4%) |
 Angina or coronary artery bypass | 0 |
 Myocardial infarction ever | 0 |
 Cardiomyopathy (ventricular dysfunction) | 2 (3.4%) |
 Valvular disease | 0 |
 Pericarditis for 6 months | 0 |
Peripheral vascular | 1 (1.7%) |
 Claudication for 6 months | 0 |
 Minor tissue loss | 0 |
 Significant tissue loss ever | 0 |
 Venous thrombosis with swelling, ulceration or venous stasis | 1 (1.7%) |
Gastrointestinal b | 0 |
Musculoskeletal | 7 (11.9%) |
 Muscle atrophy or weakness | 1 (1.7%) |
 Deforming or erosive arthritis | 0 |
 Osteoporosis with fracture or vertebral collapse | 0 |
 Avascular necrosis (unilateral) | 3 (5.1%) |
 Bilateral avascular necrosis | 3 (5.1%) |
 Osteomyelitis | 0 |
Skin | 3 (5.1%) |
 Scarring chronic alopecia | 0 |
 Extensive scarring or panniculum other than scalp and pulp space | 1 (1.7%) |
 Skin ulceration for > 6 months | 2 (3.4%) |
Premature gonadal failure | 0 |
Diabetes | 0 |
Malignancy | 0 |